AtriCure, Inc. (ATRC)
| Market Cap | 2.94B +66.1% |
| Revenue (ttm) | 569.62M +13.9% |
| Net Income | 10.55M |
| EPS | 0.21 |
| Shares Out | 50.87M |
| PE Ratio | 274.06 |
| Forward PE | 242.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 850,920 |
| Open | 57.83 |
| Previous Close | 57.30 |
| Day's Range | 56.27 - 58.44 |
| 52-Week Range | 25.36 - 61.70 |
| Beta | 1.25 |
| Analysts | Buy |
| Price Target | 55.78 (-3.46%) |
| Earnings Date | Nov 3, 2026 |
About ATRC
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation Sys... [Read more]
Financial Performance
In 2025, AtriCure's revenue was $534.53 million, an increase of 14.88% compared to the previous year's $465.31 million. Losses were -$11.45 million, -74.39% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ATRC stock is "Buy." The 12-month stock price target is $55.78, which is a decrease of -3.46% from the latest price.
News
AtriCure to Announce Third Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure price target raised to $63 from $55 at BTIG
BTIG raised the firm’s price target on AtriCure (ATRC) to $63 from $55 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
AtriCure downgraded to Hold from Buy at Freedom Capital
Freedom Capital analyst Keith Hinton downgraded AtriCure (ATRC) to Hold from Buy with a price target of $57, up from $43. The firm expects BoX-NoAF POAF data that should be…
AtriCure Transcript: Wells Fargo 21st Annual Healthcare Conference
Management outlined progress ahead of long-term targets, with strong growth in pain management and clinical trials advancing faster than planned. New product launches and ongoing investments in innovation are expected to sustain momentum, while market expansion and quality initiatives provide additional growth catalysts.
AtriCure price target raised to $60 from $50 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on AtriCure (ATRC) to $60 from $50 and keeps an Overweight rating on the shares. Earlier this year, STS introduced…
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure price target raised to $55 from $45 at BTIG
BTIG raised the firm’s price target on AtriCure (ATRC) to $55 from $45 and keeps a Buy rating on the shares. The company’s new STS Quality Metric could increase use…
AtriCure Transcript: Canaccord Genuity's 46th Annual Growth Conference
Management highlighted strong growth, profitability, and leadership in AFib and pain management, with major clinical trials set to expand market opportunities. Financial performance is robust, driven by innovation and operational leverage, while competitive differentiation is maintained through proprietary technology and clinical evidence. Free cash flow will support organic growth and R&D.
AtriCure price target lowered to $50 from $55 at UBS
UBS lowered the firm’s price target on AtriCure (ATRC) to $50 from $55 and keeps a Buy rating on the shares. Business growth excluding MIS is expected to support sustainable…
AtriCure to Participate at Upcoming Investor Conferences
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Earnings Call Transcript: Q2 2026
Q2 2026 saw 12.8% revenue growth, strong profitability, and margin expansion, led by pain management and appendage management. Strategic clinical trials and new product launches support future growth, while guidance for 2026 was raised for both revenue and adjusted EBITDA.
AtriCure Earnings release: Q2 2026
AtriCure released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
AtriCure Quarterly report: Q2 2026
AtriCure has published its Q2 2026 quarterly earnings report on July 23, 2026.
AtriCure Slides: Q2 2026
AtriCure has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
AtriCure reports Q2 adjusted EPS 18c, consensus 2c
Reports Q2 revenue $153.6M, consensus $151.81M. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive...
AtriCure sees FY26 adjusted EPS 24c-32c, consensus 12c
Narrows FY26 revenue view to $602M-$610M from $600M-$610M, consensus $604.63M.
AtriCure Reports Second Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Announce Second Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
BTIG says AtriCure should be ready to defend AtriClip share after Edwards nod
BTIG analyst Marie Thibault notes that the FDA’s 510(k) database reflected clearance of Edwards Lifesciences’ (EW) ECLIPTIS left atrial appendage exclusion system, which the analyst says is positioned...
FDA posts approval of Edwards left atrial appendage system
The FDA posted 510(k) Premarket Notification approval of Edwards Lifesciences’ (EW) Ecliptis Left Atrial Appendage Exclusion System. Shares of AtriCure (ATRC) are down 7%, or $2.09, to $28.10 followin...
AtriCure management to meet with Piper Sandler
Meeting to be held in London on June 25 and in Zurich on June 26 hosted by Piper Sandler.
AtriCure Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a strategy to reach $1 billion in revenue by 2030, driven by market expansion, innovation, and robust clinical trials. Despite competitive pressures, consistent double-digit growth is expected, with new products and clinical data serving as key catalysts. Internal investment remains the priority for future growth.
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and amendments to stock plans. All proposals, including executive compensation, were approved with over 91% of shares voted. No questions were raised during the session.
AtriCure Transcript: Bank of America Global Healthcare Conference 2026
Guidance for 2026 targets 12%-14% revenue growth, driven by innovation and new product launches, with profitability and positive cash flow expected to improve further. Major clinical trials and guideline changes are set to expand the addressable market, while competitive differentiation is reinforced by exclusive data and next-generation products.